The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Smoking Cessation For Youth Project Booster And Cohort Tracking Study
Funder
National Health and Medical Research Council
Funding Amount
$135,550.00
Summary
Adolescence is a critical period for the establishment of adult drug use behaviours. If smoking does not commence in teenage years it is unlikely to occur. This innovative project not only continues to address tobacco control with this important age group but also builds on evidence from a randomised intervention trial involving over 4,000 Year 9 students tracked over two years. This project was called the Smoking Cessation for Youth Project (SCYP). Preliminary longitudinal analyses of the SCYP ....Adolescence is a critical period for the establishment of adult drug use behaviours. If smoking does not commence in teenage years it is unlikely to occur. This innovative project not only continues to address tobacco control with this important age group but also builds on evidence from a randomised intervention trial involving over 4,000 Year 9 students tracked over two years. This project was called the Smoking Cessation for Youth Project (SCYP). Preliminary longitudinal analyses of the SCYP data indicate that the intervention students were significantly less likely to smoke heavily (smoking five or more days per week) than the control group and that intervention students were also significantly less likely to have tried smoking than the control group. These results represent a world first in evidence that population-based smoking cessation interventions among teenagers can be successful. The proposed project will determine the extent to which these positive intervention effects are sustainable, two years post intervention, as our cohort moves into Year 12. In addition to tracking the possible decay of SCYP intervention effects, the proposed project will also measure the effects of a booster intervention delivered students when they are in Year 12 (2002). The Year 12 intervention will comprise an innovative self-help 'magazine style' booster and a supportive environmental intervention involving school nurses and local GPs. This proposal represents a cost-effective opportunity to measure the effectiveness of a Year 12 tobacco cessation booster intervention. Further data on tobacco smoking behaviour in 2002 will also enable us to determine how long the SCYP intervention appears to affect behaviour and whether 'boosters' are needed in later secondary school years to maintain the benefits.Read moreRead less
Antimalarial Drugs In Pregnancy: Preclinical And Clinical Studies Of Conventional And Novel Agents
Funder
National Health and Medical Research Council
Funding Amount
$470,115.00
Summary
Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chlor ....Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chloroquine and Fansidar. There are two main issues with this approach. First, the efficacy of such conventional agents is waning and this increases the risk of break-through malaria. Second, there are few data on how the drugs are handled in pregnancy on which to base recommendations for treatment. We plan to collect information on the disposition and effectiveness of chloroquine and Fansidar in women with malaria in pregnancy in PNG that should allow a critical appraisal of the usefulness of current regimens in PNG and in other tropical countries where parasite resistance to these agents is emerging. Artemisinin combination therapy (ACT) in the form of a novel artemisinin drug and a longer-acting partner has been suggested as the most promising alternative therapy for malaria in pregnancy if conventional drugs fail. We plan to assess the safety of a leading ACT formulation, namely dihydroartemisinin and the chloroquine-like drug piperaquine (DHA-PQ), in animals before extending our studies to women with malaria in PNG. These latter studies will allow an evaluation of the safety and efficacy of DHA-PQ as novel therapy for malaria in pregnancy in PNG and other tropical countries.Read moreRead less
Translating New Therapeutics And Diagnostics For Major Pregnancy Complications
Funder
National Health and Medical Research Council
Funding Amount
$481,156.00
Summary
My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are developing new drug treatments for ectopic pregnancy (a dangerous condition where the pregnancy implants in the Fallopian tube), and preeclampsia (a condition where toxins leak out of the placenta into mum's blood, and can seriously injure many of mum's major organs). We are also generating a blood test that may help women avoid the tragedy of a stillbirth.
Development Of Vinorelbine As A Tablet Based Therapy To Cure Ectopic Pregnancies
Funder
National Health and Medical Research Council
Funding Amount
$361,594.00
Summary
Ectopic pregnancies occur if the pregnancy implants in the Fallopian tube. They can be deadly and most are treated surgically. We will examine the exciting possibility that instead of surgery, ectopic pregnancies may be cured with a tablet taken just once. We will perform laboratory studies and a clinical trial, giving vinorelbine to women with ectopic pregnancies.
Improving Strategies To Support Pregnant Aboriginal Women To Quit Smoking
Funder
National Health and Medical Research Council
Funding Amount
$380,891.00
Summary
The overall objective of this project is to produce new knowledge about effective strategies for decreasing the smoking rates in pregnant Aboriginal women. The studies aim to: 1. Understand pregnant Aboriginal smokers attitudes to and experiences of using quit smoking methods 2. Understand what behaviour change techniques may be useful for pregnant Aboriginal women who smoke 3. Explore clinicians’ knowledge, attitudes and practices of providing behavioural counselling and nicotine replacemen
Targeting The Anti-angiogenic Factors Of Preeclampsia: Soluble Endoglin And SFlt1
Funder
National Health and Medical Research Council
Funding Amount
$447,024.00
Summary
Preeclampsia is a severe disease of pregnancy - the placenta releases toxins in to mum's bloodstream that circulate her body and damage her organs. As there are no efficacious treatments, clinicians are forced to deliver babies irrespective of gestation. Although the two toxins of preeclampsia have been identified, little is known about their regulation. This project aims to elucidate the regulation of these toxins and design therapeutics that can prevent their release in the clinic.
Combination Methotrexate And Gefitinib To Cure Ectopic Pregnancies: Phase I-II Clinical Trials
Funder
National Health and Medical Research Council
Funding Amount
$235,875.00
Summary
Ectopic pregnancies are dangerous emergencies that can cause fatal bleeding. Most require surgery. We plan to test a novel medication-based treatment that could be used to cure most ectopics. If successful, it could revolutionise current management.
Soluble Endoglin In The Pathogenesis Of Preeclampsia: Investigation Of Mechanisms And The Development Of Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$572,733.00
Summary
Preeclampsia is a severe disease of pregnancy. As the pathogenesis is poorly understood, the only treatment is for clinicians to deliver babies irrespective of gestation. We have identified MMP-14 as the molecular scissors that release soluble endoglin from placenta, a toxin centrally responsible for severe preeclampsia. In this project we aim to further investigate the mechanisms governing soluble endoglin release and to begin developing a potential therapeutic for use in the clinic.
Quit In General Practice: A Cluster Randomised Trial Of Enhanced In-practice Support For Smoking Cessation
Funder
National Health and Medical Research Council
Funding Amount
$1,117,241.00
Summary
Tobacco smoking remains the most common preventable cause of death and illness in Australia today. Smoking cessation programs are some of the most effective and cost effective strategies that can be undertaken in health care settings, including general practice. This project will test a new approach to supporting smoking cessation in general practice. This involves the practice nurse, GP and Quitline working in partnership to provide a flexible program of suport to meet the needs of smokers.
Developing Diagnostics And Therapeutics For Preeclampsia: Targeting A Novel Placental Specific SFlt-1 Variant
Funder
National Health and Medical Research Council
Funding Amount
$722,283.00
Summary
Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects ....Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects of sFlt-1 as a strategy to develop drugs.Read moreRead less